Clinical Trial in Patients With Barth Syndrome- 4TAZPower

Official title

Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients With Genetically Confirmed Barth Syndrome

Overview

Phase 3b/4, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of a once daily SC injection of elamipretide in subjects with genetically confirmed BTHS for 72 weeks. The primary trial objective is to confirm the efficacy of elamipretide which is approved in the United States(FORZINITY™) under the accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint.

Detailed description

The SPIBA-401 trial is a post marketing Phase 3b/4, randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of a once daily subcutaneous (SC) injection of elamipretide in subjects with genetically confirmed Barth syndrome (BTHS) for 72 weeks. The primary trial objective is to confirm the efficacy of elamipretide which is approved in the United States under the name FORZINITY™ as a mitochondrial cardiolipin binder indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication is approved in the United States under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint.

Interventions

• Drug Elamipretide
  sub cutaneous injection
• Drug Placebo
  sub cutaneous injection

Primary outcome measures

• Primary Efficacy End Point [Time frame: 72 weeks]

Secondary outcome measures (7)

• Secondary Efficacy End Point 1 [Time frame: 72 weeks]
• Secondary Efficacy End Point 2 [Time frame: 72 weeks]
• Secondary Efficacy End Point 3 [Time frame: 72 weeks]
• Secondary Efficacy End Point 4 [Time frame: 72 weeks]
• Secondary Efficacy End Point 5 [Time frame: 72 weeks]
• Secondary Efficacy End Point [Time frame: 72 weeks]
• Secondary Efficacy End Point 6 [Time frame: 72 weeks]

Eligibility criteria

Inclusion criteria

• Willing and able to provide signed informed consent form (ICF) prior to participation in any trial-related procedures. If applicable, informed consent in writing from parent(s) or legally-acceptable representative(s) and, informed assent from subject (if age appropriate according to local requirements) should be provided.
• Agrees to adhere to the trial requirements for the length of the trial.
• Must have genetically confirmed Barth Syndrome (pathogenic variant in the TAZ gene)
• Male aged ≥ 5 years at time of the Screening Visit
• Left Ventricular Ejection fraction of ≥ 50% by 3-D Echocardiogram at the Screening Visit.
• For subjects with a medical history of cardiomyopathy, must be on a stable regimen (unchanged and constant) of background heart failure medications for at least 3 months prior to the Screening Visit.
• Able to administer Investigational Medicinal Product (IMP) or have an appropriate designee who can administer the IMP (i.e., a capable family member or a caregiver).
• Subjects with female partners of childbearing potential must be willing to use a highly effective method of contraception (e.g., abstinence, dual method of contraception) from the date they sign the ICF until 28 days after the last dose of IMP.

Exclusion criteria

• Unable to perform the required functional tests or undergo echocardiography.
• History of solid organ transplant, except successful cardiac transplantation > 12 months prior to screening, if, in the opinion of the Investigator, there is no evidence of organ rejection and post-transplant pharmacotherapy, is stable, and does not pose additional safety risk to participant.
• Patients with an implantable cardioverter defibrillator (ICD) and with a known occurrence of ICD discharge in the 3 months prior to the Screening Visit.
• Current placement on the waiting list for heart transplantation.
• Hospitalization for heart failure within 6 months prior to the Screening Visit.
• Any disease or medical condition that in the opinion of the Investigator would prevent the subject from successfully participating in the trial and reliably completing the assessments or might confound trial results.
• Has a history of a systemic eosinophilic illness
• Estimated Glomerular Filtration Rate (eGFR) of < 30 mL/min at the Screening Visit (using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 formula for subjects >16 years of age and the Schwartz 2009 formula for subjects 5-16 years of age).
• Active malignancy or any other cancer from which the subject has been cancer-free for < 2 years. Localized squamous or non-invasive basal cell skin carcinomas are allowed, if appropriately treated prior to Screening.
• Participation in other investigational drug or device clinical trials within 30 days or 5 half-lives (whichever is longer) of Screening; or is currently enrolled in a non-interventional clinical trial that, in the opinion of the Investigator, may be potentially confounding to the results of the current trial.
• History of allergic reaction to the IMP or any of its components.
• Prior participation in any elamipretide trial or expanded access programs.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Quadruple blind

Primary purpose

Treatment

Study locations

United States · 1 center

• Trial Not Offered in the U.S — Needham

Canada · 1 center

• Metabolics and Genetics in Canada (MAGIC) — Calgary

United Kingdom · 1 center

• Bristol Royal Hospital for Children Upper Maudlin Street Paul O'Gorman Building — Bristol

Identifiers

NCT: NCT07531251 · SPIBA-401

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗